What do the results of the SelectMDx test mean?
SelectMDx for prostate cancer is a non-invasive urine test. It measures the amount of two genes that are associated with aggressive prostate cancer in urine. This is combined with clinical information to assess a man’s risk of having aggressive prostate cancer.
The SelectMDx report provides an individualised likelihood that prostate cancer will be found when performing a prostate biopsy. There are two scenarios:
- Very low risk of prostate cancer: the possibility of cancer cells being present upon a biopsy is very low. This allows you and your physician to make the informed choice about delaying or avoiding a prostate biopsy.
- Risk of prostate cancer: The risk score for having prostate cancer, especially the likelihood for aggressive prostate cancer detected upon prostate biopsy is very important for determining next steps. You and your physician can make the informed choice to undergo or delay a prostate biopsy.
As with any test, aggressive prostate cancer may be present in men even if you have a very low risk outcome. For the SelectMDx test, this chance is only 2%.
Read more about the available options in case of an elevated PSA.